Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Retreatment Strategies for Difficult-to-Treat Hepatitis C Virus (HCV)-Infected Individuals Who Have Failed Prior Direct Acting Antiviral (DAA)-Based Regimens

NCT02605304 is registered in ClinicalTrials.gov with Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections as lead sponsor.

NCT NCT02605304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02605304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Retreatment Strategies for Difficult-to-Treat Hepatitis C Virus (HCV)-Infected Individuals Who Have Failed Prior Direct Acting Antiviral (DAA)-Based Regimens
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase
Phase 2
Overall status
Terminated
Start date
February 17, 2016
Completion date
March 20, 2017
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, hiv-1 infection